WA
TEVA icon

Winfield Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Winfield Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-500
Closed -$26K – 310
2014
Q1 		$26K Hold
500
– – 0.02% 189
2013
Q4 		$20K Buy
+500
New +$19.7K 0.02% 209

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Winfield Associates's TEVA Position: Q2 2014 in Review

Winfield Associates sold out of Teva Pharmaceuticals (TEVA) in Q2 2014, closing a stake of 500 shares — an estimated $26K sold.

Winfield Associates first reported a position in TEVA in Q4 2013 and held it in 2 quarters. The position peaked at $26K in Q1 2014. 779 funds tracked by Wall St. Rank hold TEVA as of Q2 2014.

  • Winfield Associates reported no remaining Teva Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Winfield Associates sold 500 Teva Pharmaceuticals shares in Q2 2014, an estimated $26K.
  • Winfield Associates first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Winfield Associates's Teva Pharmaceuticals position peaked at $26K in Q1 2014.
  • 779 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2014.

Based on Winfield Associates's 13F filing for Q2 2014, filed 28 Jul 2014.